Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1797]

MEK inhibitor, trametinib, improves progression free survival in melanoma

Dr Caroline Robert – Institute Gustave Roussy, Paris, France

MEK inhibitor, trametinib, improves progression free survival in melanoma ( Dr Caroline Robert – Institute Gustave Roussy, Paris, France )

SUCCEED trial: Maintenance treatment in advance soft tissue sarcoma

Dr Jean Yves-Blay - University Claude Bernard, Lyon, France

SUCCEED trial: Maintenance treatment in advance soft tissue sarcoma ( Dr Jean Yves-Blay - University Claude Bernard, Lyon, France )

Drug development in small cell and non-small cell lung cancer

Dr Leora Horn - Vanderbilt-Ingram Cancer Center, Nashville, USA

Drug development in small cell and non-small cell lung cancer ( Dr Leora Horn - Vanderbilt-Ingram Cancer Center, Nashville, USA )

ASCO 2012 Drug Development Research Professorship

Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA

ASCO 2012 Drug Development Research Professorship ( Dr Alex Adjei - Roswell Park Cancer Institute, Las Vegas, USA )

Early phase trial of ibrutinib for chronic lymphocytic leukaemia

Dr Samantha Jaglowski - Ohio State University Medical Center, Columbus, USA

Early phase trial of ibrutinib for chronic lymphocytic leukaemia ( Dr Samantha Jaglowski - Ohio State University Medical Center, Columbus, USA )

Treating metastatic melanoma with vemurafenib

Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA

Treating metastatic melanoma with vemurafenib ( Dr Paul Chapman – Memorial Sloan-Kettering Cancer Center, New York, USA )

Clinical trials for rare tumour types

Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA

Clinical trials for rare tumour types ( Dr William Tap – Memorial Sloan-Kettering Cancer Center, New York, USA )

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma

Dr Sagar Lonial – Emory University, Atlanta, USA

Early phase 1/2 results with oral proteasome inhibitor MLN9708 in myeloma ( Dr Sagar Lonial – Emory University, Atlanta, USA )

Effects of panitumumab against oesophageal-gastro cancer and carcinomas

Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK

Effects of panitumumab against oesophageal-gastro cancer and carcinomas ( Dr Tom Waddell – Royal Marsden Hospital, Sutton, UK )

Effects of lapatinib and trastuzumab on progression free survival

Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA

Effects of lapatinib and trastuzumab on progression free survival ( Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA )

Regorafenib effective for GISTs that progress due to resistance to approved...

Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA

Regorafenib effective for GISTs that progress due to resistance to approved targeted therapies ( Dr George Demetri - Dana-Farber Cancer Institute, Boston, USA )

ASCO 2012: Advances in myeloma

Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof...

ASCO 2012: Advances in myeloma ( Dr Philippe Moreau - Centre Hospitalier Universitaire de Nantes, France; Prof Gareth Morgan - Royal Marsden Hospital, UK )

More from ecancer